Industry update: the latest developments in the field of therapeutic delivery, November 2021

Therapeutic DeliveryVol. 13, No. 3 Industry NewsIndustry update: the latest developments in the field of therapeutic delivery, November 2021Peter TimminsPeter Timmins *Author for correspondence: Tel.: +44 1484 473 102; E-mail Address: p.timmins@hud.ac.ukhttps://orcid.org/0000-0002-5840-0678Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, UKSearch for more papers by this authorPublished Online:7 Feb 2022https://doi.org/10.4155/tde-2022-0006AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibody–drug conjugatecell therapiesclinical trialsCOVID-19drug deliverygene therapymergers and acquisitionsproduct approvalsrare diseasestargeted therapeuticsReferences1. Novo Nordisk to Acquire Dicerna. https://investors.dicerna.com/news-releases/news-release-details/novo-nordisk-acquire-dicernaGoogle Scholar2. Arrowhead Pharmaceuticals enters exclusive license agreement with GSK for ARO-HSD. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-enters-exclusive-license-agreement-gskGoogle Scholar3. iX Biopharma signs exclusive license agreement for Wafermine and other sublingual ketamine wafer products. www.ixbiopharma.com/wp-content/uploads/2021/11/Press-Release-Wafermine-out-licensing.pdfGoogle Scholar4. Seelos Therapeutics announces acquisition of an exclusive license of iX Biopharma's proprietary wafer-based delivery platform for sublingual ketamine. https://seelos.irpass.com/profiles/investor/NewsPrint.asp?v=6&b=2376&ID=104187&m=rl&g=1201Google Scholar5. Lim CBS, Sunderland VB, Lee YHE. Solid dosage form. US 10857097 B2 (2020).Google Scholar6. SPRAVATO® (esketamine) nasal spray. www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdfGoogle Scholar7. Blueprint Medicines to expand precision therapy leadership in lung cancer with acquisition of Lengo Therapeutics. https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-expand-precision-therapy-leadership-lungGoogle Scholar8. Dragonfly Therapeutics announces Merck Opt-In of TriNKET™ immunotherapy candidate for patients with solid tumors. www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-merck-opt-in-of-trinket-immunotherapy-candidate-for-patients-with-solid-tumors-301430512.htmlGoogle Scholar9. Our Platform: triNKET™. www.dragonflytx.com/platformGoogle Scholar10. Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG. www.viforpharma.com/vifor-pharma-spearhead-development-vascular-calcification-field-through-acquisition-sanifit-therapeuticsGoogle Scholar11. Ivarsson M, Castagner B, Leroux J-C, Pasch A. Inositol derivatives for use in pathological crystallization. US Patent 10,624,909 B2 (2020).Google Scholar12. Kedalion Therapeutics secures Series B funding and announces signing of option to acquire agreement. https://kedalionthera.com/2021/11/15/kedalion-therapeutics-secures-series-b-funding-and-announces-signing-of-option-to-acquire-agreement/Google Scholar13. Kedalion Therapeutics: technology. https://kedalionthera.com/technology/Google Scholar14. U.S. Food and Drug Administration approves Vuity™ (pilocarpine HCI ophthalmic solution) 1.25%, the first and only eye drop to treat presbyopia (age-related blurry near vision). https://news.abbvie.com/news/press-releases/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-125-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision.htmGoogle Scholar15. Organon to Acquire Forendo Pharma. www.organon.com/news/organon-to-acquire-forendo-pharma/Google Scholar16. Aptose enters into exclusive worldwide license agreement with Hanmi Pharmaceutical for clinical-stage myeloid kinome inhibitor HM43239. www.aptose.com/news-media/press-releases/detail/214/aptose-enters-into-exclusive-worldwide-license-agreementGoogle Scholar17. Turnstone Biologics announces research collaboration with Moffitt Cancer Center to advance novel TIL immunotherapies for solid tumor indications. www.businesswire.com/news/home/20211129005249/en/Turnstone-Biologics-Announces-Research-Collaboration-with-Moffitt-Cancer-Center-to-Advance-Novel-TIL-Immunotherapies-for-Solid-Tumor-IndicationsGoogle Scholar18. Turnstone Biologics: our science. https://turnstonebio.com/#about-usGoogle Scholar19. Turnstone Biologics acquires Novel Cell Therapy Platform. www.businesswire.com/news/home/20210120005249/en/Turnstone-Biologics-Acquires-Novel-Cell-Therapy-PlatformGoogle Scholar20. Neurocrine Biosciences and Sosei Heptares announce collaboration to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders. https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-and-sosei-heptares-announce-collaborationGoogle Scholar21. BridgeBio Pharma and Helsinn Group announce strategic collaboration to co-develop and co-commercialize BridgeBio's novel GPX4 inhibitor in multiple cancer tumor types. https://bridgebio.com/news/bridgebio-pharma-and-helsinn-group-announce-strategic-collaboration-to-co-develop-and-co-commercialize-bridgebios-novel-gpx4-inhibitor-in-multiple-cancer-tumor-typesGoogle Scholar22. Gilead exercises options to three Arcus Biosciences clinical-stage programs and adds research collaboration. https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2021/Gilead-Exercises-Options-to-Three-Arcus-Biosciences-Clinical-stage-Programs-and-Adds-Research-Collaboration/default.aspxGoogle Scholar23. Arcus Biosciences: Clinical Pipeline. https://arcusbio.com/pipeline/chart/Google Scholar24. Novome Biotechnologies and Genentech enter into a strategic collaboration to develop targets against inflammatory bowel disease. http://novomebio.com/wp-content/uploads/2021/11/Novome-and-Genentech-Enter-into-Strategic-Collaboration.pdfGoogle Scholar25. Novome Biotechnologies reports positive results from a Phase I Study of NOV-001. http://novomebio.com/wp-content/uploads/2021/11/Novome-Reports-Positive-Results-from-NOV-001-Phase-1.pdfGoogle Scholar26. Biohaven and Pfizer enter strategic collaboration for the commercialization of rimegepant outside the United States. www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-enter-strategic-collaborationGoogle Scholar27. Metagenomi and Moderna establish collaboration to develop next-generation in vivo gene editing therapeutics. https://metagenomi.co/press/metagenomi-and-moderna-establish-collaboration-to-develop-next-generation-in-vivo-gene-editing-therapeutics/Google Scholar28. Metagenomi: next generation editing systems to treat disease. https://metagenomi.co/technology/Google Scholar29. Dunad Therapeutics enters strategic collaboration with Novartis. www.dunad.co.uk/post/strategic-collaboration-with-novartisGoogle Scholar30. Dunad Therapeutics: our science. www.dunad.co.uk/Google Scholar31. Clade Therapeutics raises $87 million series A financing to realize the potential of cell therapy. https://cladetx.com/2021/11/03/clade-therapeutics-raises-87-million-series-a-financing-to-realize-the-potential-of-cell-therapy-2/Google Scholar32. Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform. https://autolus.gcs-web.com/news-releases/news-release-details/blackstone-life-sciences-invest-250-million-autolus-therapeuticsGoogle Scholar33. Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells. https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-publication-describing-its-smallGoogle Scholar34. Hotblack A, Kokalaki EK, Palton MJ et al. Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction. Sci. Rep. 11, 21902 (2021).Crossref, Medline, CAS, Google Scholar35. Flagship Pioneering launches Alltrna to unlock transfer RNA biology and treat thousands of diseases with a single tRNA medicine. www.prnewswire.com/news-releases/flagship-pioneering-launches-alltrna-to-unlock-transfer-rna-biology-and-treat-thousands-of-diseases-with-a-single-trna-medicine-301418717.htmlGoogle Scholar36. Alltrna: platform. www.alltrna.com/#platformGoogle Scholar37. OcuTerra raises $35 million series B financing. www.businesswire.com/news/home/20211109005504/en/OcuTerra-Raises-35-Million-Series-B-FinancingGoogle Scholar38. OcuTerra: science. www.ocuterratx.com/scienceGoogle Scholar39. Acrivon Therapeutics closes oversubscribed $100 million series B financing to advance its innovative precision proteomics platform and clinical oncology pipeline. https://acrivon.com/news-press/acrivon-therapeutics-closes-oversubscribed-100-million-series-b-financing-to-advance-its-innovative-precision-proteomics-platform-and-clinical-oncology-pipeline/Google Scholar40. Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9. www.globenewswire.com/news-release/2021/11/10/2331404/0/en/Exavir-Therapeutics-announces-preclinical-data-demonstrating-complete-elimination-of-HIV-from-human-cells-with-LNP-delivered-Tat-targeted-CRISPR-Cas9.htmlGoogle Scholar41. Herskovitz J, Hasan M, Patel M et al. CRISPR-Cas9 mediated exonic disruption for HIV-1 elimination. EBioMedicine 73, 103678 (2021).Crossref, Medline, Google Scholar42. Cardiff Oncology announces $15 million equity investment from Pfizer through its Pfizer breakthrough growth initiative. https://cardiffoncology.investorroom.com/2021-11-18-Cardiff-Oncology-Announces-15-Million-Equity-Investment-from-Pfizer-through-its-Pfizer-Breakthrough-Growth-InitiativeGoogle Scholar43. Cardiff Oncology: ovansertib. https://cardiffoncology.com/onvansertib/Google Scholar44. Cardiff Oncology company overview: the onvansertib opportunity. https://cardiffoncology.com/wp-content/uploads/2021/11/11-18-21-Cardiff-Corporate-Presentation-PDF-Version-Read-Only_compressed.pdfGoogle Scholar45. EsoCap secures new funding. https://esocapbiotech.ch/2021/11/18/esocap-secures-new-funding/Google Scholar46. Krause J, Rosenbaum C, Grimm M et al. The EsoCap-system – an innovative platform to drug targeting in the esophagus. J. Control Rel. 327, 1–7 (2020).Crossref, Medline, CAS, Google Scholar47. Merck and Ridgeback's Molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world. www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/Google Scholar48. Merck and Ridgeback statement on positive FDA Advisory Committee vote for investigational oral antiviral molnupiravir for treatment of mild to moderate COVID-19 in high risk adults. www.merck.com/news/merck-and-ridgeback-statement-on-positive-fda-advisory-committee-vote-for-investigational-oral-antiviral-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults/Google Scholar49. Merck and Ridgeback announce U.S. Government to purchase 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults. www.merck.com/news/merck-and-ridgeback-announce-u-s-government-to-purchase-1-4-million-additional-courses-of-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-a/Google Scholar50. Merck and Ridgeback announce Japanese Government to purchase 1.6 million courses of molnupiravir, an investigational oral COVID-19 antiviral medicine, upon authorization or approval. www.merck.com/news/merck-and-ridgeback-announce-japanese-government-to-purchase-1-6-million-courses-of-molnupiravir-an-investigational-oral-covid-19-antiviral-medicine-upon-authorization-or-approval/Google Scholar51. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase II/III EPIC-HR study. www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidateGoogle Scholar52. Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19. www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/Google Scholar53. Pfizer seeks emergency use authorization for novel COVID-19 oral antiviral candidate. www.pfizer.com/news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19Google Scholar54. PFIZER to provide U.S. Government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19. https://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-to-Provide-U.S.-Government-with-10-Million-Treatment-Courses-of-Investigational-Oral-Antiviral-Candidate-to-Help-Combat-COVID-19/default.aspxGoogle Scholar55. Opiant Receives FDA fast track designation for OPNT003, nasal nalmefene, for treatment of opioid overdose. https://ir.opiant.com/news-releases/news-release-details/opiant-receives-fda-fast-track-designation-opnt003-nasalGoogle Scholar56. Apellis reiterates plans to submit a new drug application in the first half of 2022 for pegcetacoplan for geographic atrophy following FDA feedback. https://investors.apellis.com/news-releases/news-release-details/apellis-reiterates-plans-submit-new-drug-application-first-halfGoogle Scholar57. U.S. FDA approves Besremi® (ropeginterferon alfa-2b-njft) as the only interferon for adults with polycythemia vera. https://hq.pharmaessentia.com/uploads/images/%E2%95%96s%E2%95%97D%E2%96%91%E2%95%A9%E2%95%91A/latest%20news/202111/BESREMi%20FDA%20Approval%20November%2012%202021%20HQ.pdfGoogle Scholar58. Bristol Myers Squibb's applications for deucravacitinib for the treatment of moderate to severe plaque psoriasis accepted by U.S. Food and Drug Administration and validated by European Medicines Agency. https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibbs-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency/default.aspxGoogle Scholar59. Aadi Bioscience announces FDA approval of its first product Fyarro™ for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). https://ir.aadibio.com/news-releases/news-release-details/aadi-bioscience-announces-fda-approval-its-first-productGoogle Scholar60. Aadi Bioscience: the technology platform. https://aadibio.com/the-product/Google Scholar61. Pacific pride: abraxis veteran grooms dormant Celgene drug for success. https://ir.aadibio.com/node/8601/pdfGoogle Scholar62. Sangamo Therapeutics announces preliminary Phase I/II data showing tolerability and sustained elevated α-Gal A enzyme activity in patients with fabry disease. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-preliminary-phase-12-data-showingGoogle Scholar63. Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants. www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=543&pagenumber=1&keyword=&keyword_type=Google Scholar64. Celltrion's monoclonal antibody treatment regdanvimab, approved by the European Commission for the treatment of COVID-19. www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=539&pagenumber=1&keyword=&keyword_type=Google Scholar65. ImmunoGen announces positive top-line results from pivotal SORAYA trial of mirvetuximab soravtansine in ovarian cancer. https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-positive-top-line-results-pivotal-sorayaGoogle Scholar66. Nuber S, Nam AY, Rajsombath MM et al. A stearoyl–coenzyme a desaturase inhibitor prevents multiple Parkinson Disease phenotypes in α-synuclein mice. Ann. Neurol. 89, 74–90 (2021).Crossref, Medline, CAS, Google Scholar67. Yumanity Therapeutics announces positive top-line results of Phase Ib clinical trial for YTX-7739 in patients with Parkinson's Disease; company plans to advance program to Phase II. www.yumanity.com/investor-relations/press-releases/Google Scholar68. AlgoTherapeutix completes Phase I for peripheral neuropathy program ATX01, poised for Phase II initiation in 2022. https://algotx.com/algotherapeutix-completes-phase-i-for-peripheral-neuropathy-program-atx01-poised-for-phase-ii-initiation-in-2022/Google Scholar69. Genevois A-L, Ruel J, Penalba V et al. Analgesic effects of topical amitriptyline in patients with chemotherapy-induced peripheral neuropathy: mechanistic insights from studies in mice. J. Pain 22, 440–452 (2021).Crossref, Medline, CAS, Google Scholar70. AZD8601 EPICCURE Phase II trial demonstrated safety and tolerability in patients with heart failure. www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd8601-epiccure-phase-ii-trial-demonstrated-safety-and-tolerability-in-patients-with-heart-failure.htmlGoogle Scholar71. Protagonist Therapeutics announces positive Phase IIa data supporting the potential use of rusfertide as a first-in-class therapy in hereditary hemochromatosis. https://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-announces-positive-phase-2a-dataGoogle Scholar72. Immatics reports clinical responses across multiple solid tumor types in ongoing ACTengine® IMA203 Phase Ia trial targeting PRAME. https://investors.immatics.com/news-releases/news-release-details/immatics-reports-clinical-responses-across-multiple-solid-0Google Scholar73. Aldeyra Therapeutics announces achievement of primary endpoint of ocular redness in randomized, double-masked, vehicle-controlled Phase II clinical trial in dry eye disease. https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-achievement-primary-endpointGoogle ScholarFiguresReferencesRelatedDetails Vol. 13, No. 3 Follow us on social media for the latest updates Metrics Downloaded 55 times History Received 18 January 2021 Accepted 20 January 2022 Published online 7 February 2022 Published in print March 2022 Information© 2022 Newlands PressKeywordsantibody–drug conjugatecell therapiesclinical trialsCOVID-19drug deliverygene therapymergers and acquisitionsproduct approvalsrare diseasestargeted therapeuticsFinancial & competing interests disclosureThe author is a former employee, and is a current shareholder, of Bristol-Myers Squibb, which has active research programs and marketed medicines in some of the therapeutic areas covered in this article. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download